Novartis probes controversy around Diovan studies

Novartis ($NVS) has opened an investigation after learning that a company employee was affiliated with a study of its blood pressure drug Diovan as a statistician without revealing his ties to the Swiss healthcare giant. It's the latest in a widening controversy over studies of the big-market drug, including retracted papers co-authored by former Kyoto Prefectural University researcher Hiroaki Matsubaba. But now one of Novartis' own employees has been ensnared in the controversy, Forbes reported. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.